For this proof of concept study, we selected CUB-domain-containing-protein-1 (CDCP1) as the primary antibody (Ab) target, because this integral membrane protein is highly expressed at the cell surface of various cancer types and hence allowed testing of the ATPP approach in multiple tumor cell lines (10–13). Here, CDCP1 is linked to cancer.